You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR TAMIFLU


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TAMIFLU

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00298233 ↗ High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed University of Oxford Phase 2 2006-02-01 Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 ↗ High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed Wellcome Trust Phase 2 2006-02-01 Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 ↗ High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed World Health Organization Phase 2 2006-02-01 Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 ↗ High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2006-02-01 Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TAMIFLU

Condition Name

Condition Name for TAMIFLU
Intervention Trials
Influenza 45
Healthy 4
Healthy Volunteer 4
Influenza, Human 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TAMIFLU
Intervention Trials
Influenza, Human 49
Infections 7
Infection 5
Respiratory Tract Infections 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TAMIFLU

Trials by Country

Trials by Country for TAMIFLU
Location Trials
United States 303
Canada 41
Australia 19
Spain 17
Italy 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TAMIFLU
Location Trials
California 15
New York 14
Texas 14
Pennsylvania 13
Florida 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TAMIFLU

Clinical Trial Phase

Clinical Trial Phase for TAMIFLU
Clinical Trial Phase Trials
Phase 4 23
Phase 3 9
Phase 2/Phase 3 2
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TAMIFLU
Clinical Trial Phase Trials
Completed 49
Terminated 8
Withdrawn 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TAMIFLU

Sponsor Name

Sponsor Name for TAMIFLU
Sponsor Trials
Hoffmann-La Roche 24
National Institute of Allergy and Infectious Diseases (NIAID) 7
University of Oxford 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TAMIFLU
Sponsor Trials
Other 52
Industry 42
NIH 11
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.